Welcome to our dedicated page for Arbe Robotics Ltd. SEC filings (Ticker: ARBE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Arbe Robotics Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Arbe Robotics Ltd.'s regulatory disclosures and financial reporting.
Arbe Robotics Ltd. received an updated ownership filing showing that venture fund Canaan Partners Israel and related entities, along with Ehud M. Levy, report significant holdings in the company’s ordinary shares.
Canaan Partners Israel (CPI) (Cayman) L.P. directly owns 7,840,262 ordinary shares, representing about 7.2% of the class. Its general partners, Canaan Partners Israel (CPI) GP, L.P. and Canaan Partners Israel (A.G.P) 1 Ltd, may each be deemed to beneficially own the same 7,840,262 shares.
Ehud M. Levy, as the control person of these entities, may be deemed to beneficially own 7,893,595 ordinary shares, or roughly 7.3% of the company. This includes 53,333 shares underlying stock options exercisable within 60 days of December 31, 2025. All ownership percentages are based on 108,859,502 ordinary shares outstanding as of September 30, 2025.
Arbe Robotics Ltd. is scheduling a live conference call on February 26, 2026 at 8:30 a.m. Eastern Time to discuss its fourth quarter 2025 and full year 2025 financial results, which will be released earlier that day before the U.S. market opens.
The call will feature CEO Kobi Marenko and CFO Karine Pinto-Flomenboim, and will be accessible via webcast on Arbe’s investor relations website or by toll-free phone numbers in the U.S., Israel and internationally. A replay webcast will be available the following day.
Arbe describes itself as a global leader in ultra-high-resolution automotive radar chipsets supporting advanced driver-assistance and autonomous driving systems, and reiterates standard forward-looking statement warnings referencing geopolitical, macroeconomic and currency risks noted in its prior annual report.
Arbe Robotics Ltd. launched an underwritten registered direct offering of 13,225,000 ordinary shares, including 1,725,000 shares from full exercise of the over-allotment option, at a public price of $1.40 per share, for gross proceeds of about $18.5 million before fees and expenses. Canaccord Genuity is sole bookrunner, with Roth Capital Partners and WestPark Capital as co-managers. Arbe will use the net proceeds for working capital and general corporate purposes. The company agreed to pay underwriters a 6% commission on gross proceeds plus $125,000 of expense reimbursement and accepted a 90‑day lockup on issuing or registering additional equity, subject to limited exceptions. The transaction is expected to close on January 27, 2026, under an existing effective Form F‑3 shelf registration.
Arbe Robotics Ltd. is conducting a primary offering of 11,500,000 ordinary shares at $1.40 per share under its shelf registration. The underwriters have a 30‑day option to buy up to 1,725,000 additional shares, which would increase the deal size if fully exercised.
The company expects gross proceeds of $16.1 million and approximately $15.1 million in proceeds before expenses, or $17.4 million if the option is fully exercised. After underwriting fees and estimated expenses, net proceeds are estimated at about $14.8 million, or $17.1 million with full option exercise.
Arbe plans to use the cash for working capital and general corporate purposes108,859,502 as of September 30, 2025 and are expected to be 120,359,502 after the offering, or 122,084,502 if the option is fully exercised, meaning existing holders are diluted but the company gains additional funding to support its 4D imaging radar business.
Arbe Robotics Ltd. has filed a Form F-3 to register 6,044,071 ordinary shares issuable upon conversion of debentures with an aggregate principal amount of NIS 57,600,000 (approximately $18 million at the issuance-date exchange rate). These debentures, issued in Israel and listed on the TASE under ARBE.C1, bear interest of 6.5% until December 31, 2025 and 4.35% thereafter, mature on May 30, 2028, and are convertible at NIS 9.53 (approximately $2.95) per share. The debenture proceeds of approximately NIS 50,227,200 (approximately $15.7 million) are held in escrow and will be released to Arbe if specified conditions are met by December 31, 2026 or upon conversion, and Arbe plans to use any released funds for working capital and general corporate purposes. As of December 31, 2025, Arbe had 109,188,112 ordinary shares outstanding, and any conversion would dilute existing shareholders while giving debenture holders equity exposure at a premium to the share price noted in the document.
Arbe Robotics Ltd. has proposed amending its series A convertible bonds, including extending to December 31, 2026 the deadline for meeting conditions to release proceeds currently held by the bond trustee.
The trustee has called a bondholder vote on December 16, 2025 on the extension and updated terms, which would reduce the interest rate from 6.5% to 4.35% effective January 1, 2026, while keeping the conversion price at ILS 9.53 (about $2.95) per share. If approved, the Company is considering issuing additional bonds of this series, which could increase the principal outstanding to up to $20 million, from about $8.5 million currently. Arbe notes it does not expect to secure a potential strategic program award with a European OEM in the near future, but it continues to stand by its recently announced 2026 goals.
Arbe Robotics Ltd. furnished a Form 6-K noting that it issued a press release with financial results for the quarter ended September 30, 2025, and will discuss these third quarter results on a live conference call on November 17, 2025, at 8:30 a.m. Eastern Time. The call will feature co-founder and CEO Kobi Marenko and CFO Karine Pinto‑Flomenboim and will be accessible by telephone and via webcast through the company’s investor relations website, with an archived replay available online. The filing also highlights that the press release and the conference call include forward-looking statements subject to risks such as tariffs and trade policies, the impact of terrorism and hostilities in Israel including the continuing war with Hamas in Gaza and potential intensification with other parties, possible boycotts of Israeli products and stocks, and changes in the US dollar–Israeli shekel exchange rate, as further described in the company’s Form 20-F risk factors.
Arbe Robotics Ltd. (ARBE) announced it will hold its third quarter 2025 conference call on November 17, 2025 at 8:30 a.m. Eastern Time to discuss financial results. The call will feature Kobi Marenko, co-founder and CEO, and Karine Pinto-Flomenboim, CFO.
Participants can register in advance online; dial-in options include (844) 481-3015 (toll-free U.S.), 1-809-212373 (Israel toll-free), and +1 (412) 317-1880 (international). A live webcast and an archived replay will be available via the company’s Investor Relations website.
Arbe Robotics Ltd. (ARBEW) submitted a Form 144 disclosing a proposed sale of 162,158 ordinary shares with an aggregate market value of $315,170, scheduled approximately for 09/22/2025 on NASDAQ. The securities were originally acquired in a private placement on 03/30/2016 from Arbe Robotics Ltd., totaling 4,261,734 shares at cash payment. The filing also reports recent sales by Canaan Partners Israel of 100,000 and 87,842 ordinary shares on 09/18/2025 and 09/19/2025 respectively, generating gross proceeds of $149,690.00 and $147,864.44. The filing includes the required representation that the seller is not aware of undisclosed material adverse information.